| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA2316805
Max Phase: Preclinical
Molecular Formula: C25H29N3O3
Molecular Weight: 419.53
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: COc1ccc(/C=C/C(=O)NCCCC(C)Nc2cc(OC)cc3cccnc23)cc1
Standard InChI: InChI=1S/C25H29N3O3/c1-18(28-23-17-22(31-3)16-20-7-5-15-27-25(20)23)6-4-14-26-24(29)13-10-19-8-11-21(30-2)12-9-19/h5,7-13,15-18,28H,4,6,14H2,1-3H3,(H,26,29)/b13-10+
Standard InChI Key: PUOJUOMWQKCULY-JLHYYAGUSA-N
Associated Targets(non-human)
Plasmodium berghei (192651 Activities)
Plasmodium falciparum (966862 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
L6 (7924 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mycobacterium tuberculosis (203094 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mycobacterium avium complex sp. (178 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mycobacterium avium (4587 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 419.53 | Molecular Weight (Monoisotopic): 419.2209 | AlogP: 4.66 | #Rotatable Bonds: 10 |
| Polar Surface Area: 72.48 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 4.08 | CX LogP: 3.66 | CX LogD: 3.66 |
| Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.37 | Np Likeness Score: -0.48 |
References
| 1. Pérez BC, Teixeira C, Albuquerque IS, Gut J, Rosenthal PJ, Gomes JR, Prudêncio M, Gomes P.. (2013) N-cinnamoylated chloroquine analogues as dual-stage antimalarial leads., 56 (2): [PMID:23273038] [10.1021/jm301654b] |
| 2. Perez B, Teixeira C, Albuquerque IS, Gut J, Rosenthal PJ, Prudencio M, Gomes P. (2012) PRIMACINS, N-cinnamoyl-primaquine conjugates, with improved liver-stage antimalarial activity, 3 (9): [10.1039/C2MD20113E] |
| 3. Levatić J, Pavić K, Perković I, Uzelac L, Ester K, Kralj M, Kaiser M, Rottmann M, Supek F, Zorc B.. (2018) Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity., 146 [PMID:29407988] [10.1016/j.ejmech.2018.01.062] |
| 4. Pavić K, Perković I, Pospíšilová Š, Machado M, Fontinha D, Prudêncio M, Jampilek J, Coffey A, Endersen L, Rimac H, Zorc B.. (2018) Primaquine hybrids as promising antimycobacterial and antimalarial agents., 143 [PMID:29220797] [10.1016/j.ejmech.2017.11.083] |
Source
Source(1):